Last updated: February 15, 2026
What is the drug associated with NDC 70000-0538?
NDC 70000-0538 corresponds to Sutimlimab (Brand: Enjaymo), developed by Sanofi. It is a monoclonal antibody approved by the FDA in February 2022 for the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia.
Market Size and Demographics
Cold Agglutinin Disease (CAD):
- Prevalence: Estimated at 1 to 2 cases per million annually in the U.S.
- Total diagnosed patients: Approximately 1,200 to 2,400 in the U.S.
- Treatment landscape: Limited options, primarily supportive care (steroids, plasma exchange).
Target Market:
- Limited by rarity; primarily FDA-approved for adult CAD patients.
- US patients: ~2,000, assuming low diagnosis rates and awareness.
- Global market: Limited data, but primarily in developed nations with healthcare infrastructure.
Market Dynamics and Competitive Landscape
Current Landscape:
- No branded treatments specifically approved for CAD before Sutimlimab.
- Supportive treatments: Corticosteroids, immunosuppressants, plasma exchange.
- Experimental therapies and off-label use vary, but Sutimlimab holds a unique approval niche.
Key Competitors:
- No direct branded competitors at FDA approval.
- Off-label drugs: Rituximab (monoclonal antibody), used off-label for autoimmune hemolytic anemia. Its annual sales in hematology approximate $1-2 billion globally, but not specific to CAD.
Pricing and Reimbursement:
- Sutimlimab's initial pricing set at approximately $370,000 per year per patient (list price).
- Price differs by health plan negotiations, discounts, and patient assistance programs.
Price Projections and Revenue Estimates
Initial Launch (2022):
- The drug's list price: $370,000 annually (per Sanofi's initial pricing strategy).
- Estimated U.S. sales: 150-300 patients in the first year due to rarity, with potential growth as awareness increases.
- First-year revenue: Approximately $60 million to $110 million.
Long-term Outlook (2025-2030):
- Market penetration: Likely to expand with increased diagnosis, physician familiarity.
- Patient expansion: Projected to reach 500-800 U.S. patients over five years, assuming slow uptake.
Revenue Projections Table (U.S.):
| Year |
Patients |
Estimated Revenue (Million USD) |
| 2023 |
200 |
$74 |
| 2024 |
350 |
$130 |
| 2025 |
500 |
$185 |
| 2026 |
600 |
$222 |
| 2027 |
800 |
$296 |
Global Market:
- Likely at 10-15% of U.S. sales initially, reflecting market penetration and healthcare access differences.
- Potential annual revenues of $20-50 million globally by 2025.
Factors Influencing Future Price and Market Growth
- Approval of biosimilars or generics: Not expected within the next 10 years due to patent protection and complexity of biologics.
- Pricing negotiations: Payers may negotiate discounts, affecting net revenues.
- Market acceptance: Physician familiarity and diagnosis rates influence utilization.
- Regulatory expansions: FDA or EMA approval for other indications can extend market size.
Risks and Limitations
- Small patient population limits overall market size.
- Price sensitivity among payers could suppress net revenue.
- Competition from off-label uses or new emerging therapies may impact growth.
Key Takeaways
- NDC 70000-0538 corresponds to Sutimlimab (Enjaymo), FDA-approved for CAD in 2022.
- The drug's list price is approximately $370,000 per year.
- U.S. market potential ranges from 200 to over 800 patients within five years.
- First-year revenue is estimated between $60 million and $110 million, with growth aligned to diagnosis rates and payer negotiations.
- The global market remains limited but may contribute an additional $20-50 million annually by mid-decade.
Frequently Asked Questions
Q1: What determines the drug's market price?
The price reflects factors including manufacturing costs for biologics, market exclusivity, regulatory approval, and negotiations with payers.
Q2: How might biosimilars impact Sutimlimab's price?
Biosimilars could introduce competition in the next 10 years, potentially reducing prices by 20-50%.
Q3: Are there ongoing clinical trials for additional indications?
Currently, no; Sutimlimab is approved solely for CAD. Expansion to other autoimmune hematologic conditions is under investigation.
Q4: What barriers exist for market penetration?
Limited awareness among physicians, low diagnosis rates, and high costs may slow adoption.
Q5: How does Sutimlimab's pricing compare to similar biologics?
Biologics for rare diseases often cost between $200,000 and $500,000 annually, placing Sutimlimab within typical price ranges for niche indications.
Citations:
[1] FDA. Enjaymo (Sutimlimab-jome) Prescribing Information. 2022.
[2] Sanofi. Sutimlimab (Enjaymo) Pricing and Payer Information. 2022.
[3] GlobalData. Rare Hematologic Disease Market Analysis, 2022.
